Revisiting the core unmet need: based on a science of high immediacy and high durability, tarcocimab and KSI-501 are poised to fill the ‘golden quadrant’ Mainstay intravitreal biologic monotherapies for all patients Gen 1.0 • Eylea • Lucentis • Biosimilars Gen 1.5 • Eylea HD • Vabysmo Gen 2.0 – Kodiak Intravitreal Biologic KSI-501 Tarcocimab Onerous monitoring and inflammation control. Long-term safety unknown Maintenance agents to be used in subset of patients, but always relying on mainstay biologics to (re)establish disease control Implants Gene Therapies Similar immediacy to Gen 1.0 therapies and longest durability for all patients Potential for additional efficacy beyond anti-VEGF monotherapies, while maintaining immediacy and signature durability of ABC ® platform Efficacy Durability Quadrant of core unmet need Durability Efficacy 34